IBM Quantum powered five of the six Q4Bio Challenge finalist teams, including the $2 million-winning Algorithmiq-Cleveland Clinic-IBM collaboration, demonstrating that quantum hardware can now solve real healthcare and biological problems. Researchers demonstrated that hybrid quantum-classical workflows deliver new insights in molecular simulation and drug discovery. The results highlight how quantum computing is moving from theory to practical impact in life sciences, with new discoveries that classical approaches could not achieve[1]. What is Covered in this Article - IBM Quantum’s role in enabling new healthcare and biology research outcomes - How hybrid quantum-classical workflows change research possibilities - Novel molecular structures discovered in the competition - Barriers to broader enterprise adoption in healthcare The News: IBM Quantum played a central role in the Q4Bio Challenge, a competition funded by Wellcome Leap to accelerate quantum algorithms for healthcare and biology. Five of the six finalist teams, including the $2 million grand prize winners from Algorithmiq, Cleveland Clinic, and IBM, ran their solutions on IBM’s quantum hardware. Researchers focused on near-term hardware and hybrid quantum-classical workflows, not just theoretical models. Teams reported new findings in drug discovery and molecular simulation that were not possible with classical computing alone. The competition highlighted how quantum hardware, when combined with classical resources, can address complex biological questions and accelerate the pace of discovery. “Although classical methods for biochemistry have a decades long headstart, quantum methods are really starting to become competitive,” said Ryan LaRose, a professor at Michigan State University and a researcher on a team that used an IBM Quantum Heron r2 processor to study ATP and GTP hydrolysis in proteins. “For our project, IBM hardware provided the number of qubits, gate fidelity, and sampling rate needed to make our experiments viable.” Will IBM Quantum’s Q4Bio Challenge Results Lead to Biochemistry Breakthroughs? Analyst Take: IBM